Abacus Life and Lorisco Life Announce Launch Of PREADISAN To Improve Health Predictions

Author: Benzinga Newsdesk | August 19, 2024 08:06am

• New partnership leverages PREADISAN™, the cutting-edge health prediction platform using machine learning and modern proteomics
  
  
  
   
• Applies novel big data analytics tools to the Abacus portfolio of services
  
  
  
   
• Lorisco's risk scores will enable a more personalized approach to longevity and actuarial technology to maximize value for Abacus' clients

ORLANDO, Fla and NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) --

Abacus Life, Inc. ("Abacus") (NASDAQ:ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, and Lorisco Life LLC ("Lorisco"), a health prediction company using modern proteomics and machine learning to accurately forecast health events, today announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology.

The Lorisco PREADISAN™ risk score is a novel assessment and planning tool that generates individualized insights beyond traditional statistics-based life expectancy opinions. The PREADISAN™ risk score introduces blood-based proteomic biomarker analysis coupled with clinically driven artificial intelligence (AI) models that assess mortality risks. The PREADISAN™ risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time.

Posted In: ABL